Asma persistente grave com resposta ao uso off label de omalizumabe, não obstante a IgE sérica total ser alta ou baixa

Asai, Nobuhiro; Ohkuni, Yoshihiro; Komatsu, Akina; Matsunuma, Ryo; Nakashima, Kei; Kaneko, Norihiro

doi:10.1590/s1806-37132011000400021

Cited by 5 publications

(1 citation statement)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Administration in patients with a serum IgE level < 30 IU/L was discouraged, possibly because in the initial report of patients with bronchial hyperreactivity, none had such low IgE concentrations [ 6 ]. However, there have been subsequent reports of successful omalizumab therapy in subjects with IgE levels below this reference range, patients with negative skin prick tests and nonallergic asthmatics [ 4 , 5 , 7 – 10 ].…”

Section: Discussionmentioning

confidence: 99%

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE

Divya

Venkitakrishnan

Augustine

et al. 2020

Case Reports in Pulmonology

View full text Add to dashboard Cite

Asthma is one of the most common respiratory diseases encountered in clinical practice. Although the vast majority of asthmatics can be adequately controlled with inhaled steroids and other preventer medications, a small proportion remain uncontrolled. Anti-IgE treatment with omalizumab has been proposed in patients as a preferred approach in step 5 asthma therapy according to GINA guidelines. Although therapy with this molecule is approved for patients with atopic asthma and pretreatment serum IgE levels of 30-1500 only, there have been a few reports of its efficacy in subjects outside this reference IgE range. We report the case of a middle-aged lady with severe corticosteroid-dependent asthma and low serum IgE levels who was successfully treated with 9 months of omalizumab therapy. She gained good asthma control and was tapered off steroid use by the fifth month of therapy with omalizumab. The case report stresses the need for further investigation into expanding the spectrum of omalizumab usage in asthma beyond the current IgE suitability range.

show abstract

Section: Discussionmentioning

confidence: 99%

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE

Divya

Venkitakrishnan

Augustine

et al. 2020

Case Reports in Pulmonology

View full text Add to dashboard Cite

show abstract

Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study

Maselli

Singh

Diaz

et al. 2013

Annals of Allergy, Asthma & Immunology

View full text Add to dashboard Cite

Use of Humanized Off-Label Monoclonal Antibodies in Pediatric Practice

Shnaider

Максимов

Романов

et al. 2023

Vestnik "Biomedicina i sociologiya"

View full text Add to dashboard Cite

In recent years, the use of off-label drugs (the use of drugs for indications not approved by state regulatory bodies, and also not mentioned in the instructions for use) has become widespread in the pediatric population. For a long time, clinical trials in the pediatric population were considered difficult to conduct due to ethical issues, leading to frequent off-label drug use. Off-label drug use remains an important public health problem, especially in children with rare diseases or diseases not responding to standard treatment. The purpose of the review is to analyze foreign literature sources on the use of biological preparations outside the instructions. The use of drugs outside the instructions (off-label) is a topical issue in the clinical practice of doctors of various specialties, and this is especially in demand in pediatric practice. This is due to the fact that a registered drug may have a successful experience in adults, but at the same time not have official approval for use in children. The need to use drugs outside the instructions for use, as a rule, occurs in patients with severe, chronic, life-threatening pathology. Further studies analyzing their efficacy, safety, and cost-benefit ratio are needed to expand the use of biological therapy in the pediatric population.

show abstract

Asma persistente grave com resposta ao uso off label de omalizumabe, não obstante a IgE sérica total ser alta ou baixa

Cited by 5 publications

References 9 publications

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE

Efficacy of Omalizumab Therapy in an Asthmatic with Low IgE

Efficacy of omalizumab in asthmatic patients with IgE levels above 700 IU/mL: a retrospective study

Use of Humanized Off-Label Monoclonal Antibodies in Pediatric Practice

Contact Info

Product

Resources

About